Nomogram to Predict the Survival of Chinese Patients with Alcohol-Related Liver Disease
Table 1
Baseline characteristics of patients in different cohorts.
Variable
Training cohort (n = 265)
Validation cohort (n = 114)
value
Clinical characteristic
Age, years
55.36 ± 10.83
54.03 ± 12.16
0.290
Male, n%
260 (98.1%)
112 (98.2%)
1.000
Relapse, n%
167 (63.0%)
65 (57.0%)
0.272
Smoking, n%
196 (74.0%)
76 (66.7%)
0.148
Cirrhosis, n%
216 (81.5%)
91 (79.8%)
0.701
AH, n%
99 (37.4%)
33 (28.9%)
0.115
Cancer, n%
23 (8.7%)
10 (8.8%)
0.977
Ascites, n%
177 (66.8%)
69 (60.5%)
0.241
Varices bleeding, n%
31 (11.7%)
15 (13.2%)
0.690
Encephalopathy, n%
38 (14.3%)
15 (13.2%)
0.761
Laboratory parameters
WBC (109/L)
5.33 (3.93–7.78)
5.55 (3.99–8.45)
0.435
HB (g/L)
113.00 (89.00–133.00)
110.50 (88.58–131.20)
0.796
PLT (g/L)
96.00 (63.70–144.00)
107.20 (58.75–192.25)
0.194
ALT (U/T)
29.30 (18.60–51.35)
27.00 (16.55–52.55)
0.663
AST (U/T)
59.30 (34.60–102.35)
49.35 (36.00–84.53)
0.224
TBIL (μmol/L)
44.00 (20.95–108.15)
33.80 (17.90–75.83)
0.109
ALB (g/L)
30.90 (26.25–36.00)
31.95 (26.58–36.90)
0.418
Cr (μmol/L)
66.90 (56.30–81.70)
63.80 (54.00–79.00)
0.095
PT-INR
1.32 (1.14–1.70)
1.31 (1.08–1.63)
0.236
Na (mmol/L)
138.30 (135.30–141.25)
139.50 (136.15–141.95)
0.083
Scoring system
MELD score ≥21, n%
39 (14.7%)
11 (9.6%)
0.181
Training cohort vs. validation cohort after random allocation with ratio 7 : 3. Data were reported as counts and percentages, median±standard deviation, or medians with 25th and 75th percentile, respectively. AH, alcoholic hepatitis; WBC, white blood cell; HB, haemoglobin; PLT, platelet count; ALT, alanine transaminase; AST, aspartate transaminase; TBIL, total bilirubin; ALB, albumin; Cr, creatine; PT-INR, prothrombin time-International Standardization Ratio; MELD score, model for end-stage liver diseases score.
